LeMaitre Vascular (LMAT) vs Sanara MedTech (SMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sanara MedTech (SMTI) has outperformed LeMaitre Vascular (LMAT) over the past year, gaining 8.4% versus a loss of 9.5%. Over five years, LMAT leads with a +48.6% price change compared with +6.3% for SMTI. LeMaitre Vascular is the larger company by market cap ($1.85 billion vs $322.0 million), about 5.7 times the size.
On valuation, LeMaitre Vascular trades at a lower forward P/E (25.4x vs 64.9x for Sanara MedTech). LeMaitre Vascular pays a dividend yielding 1.11%, while Sanara MedTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMAT | SMTI |
|---|---|---|
| Share price | $80.81 | $35.05 |
| Market cap | $1.85B | $322.04M |
| 1-day change | +1.47% | 0.00% |
| YTD return | -1.80% | +50.11% |
| 1-year return | -9.54% | +8.41% |
| 5-year return | +48.64% | +6.28% |
| P/E ratio (TTM) | 28.35 | — |
| Forward P/E | 25.42 | 64.91 |
| EPS (TTM) | $2.85 | $-0.04 |
| Dividend yield | 1.11% | 0.00% |
| Annual dividend | $0.90 | $0.00 |
| Revenue (latest FY) | $249.60M | — |
| Revenue growth (YoY) | +13.53% | — |
| Net income (latest FY) | $57.73M | — |
| Gross margin | 71.53% | — |
| Operating margin | 27.21% | — |
| Net margin | 23.13% | — |
| 52-week high | $118.01 | $35.34 |
| 52-week low | $78.22 | $16.05 |
| Distance from 52-week high | -31.52% | -0.82% |
| Analyst consensus | buy | none |
| Avg. price target upside | +32.41% | -0.14% |
| Average volume | 330.14K | 280.40K |
| Shares outstanding | 22.87M | 9.19M |
| Employees | 646 | 108 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LeMaitre Vascular is about 5.7 times larger than Sanara MedTech by market value ($1.85B vs $322.04M).
- SMTI has outperformed LMAT by 18.0 percentage points over the past year.
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.11% vs 0.00%).
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
LMAT vs SMTI FAQ
Which is bigger, LeMaitre Vascular or Sanara MedTech?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.85B compared with $322.04M for Sanara MedTech (SMTI).
Which stock has performed better over the past year, LMAT or SMTI?
SMTI returned +8.41% over the past 12 months, compared with -9.54% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, LeMaitre Vascular or Sanara MedTech?
LeMaitre Vascular pays a dividend yielding 1.11%, while Sanara MedTech does not currently pay a regular dividend.
Are LeMaitre Vascular and Sanara MedTech in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for LeMaitre Vascular and Industrial Specialties for Sanara MedTech.